Fat hinders TNF-alpha treatment for AS

Having a high body fat content does not bode well for treatment of ankylosing spondylitis with TNF-alpha blockers, a new study suggests.

Following 41 patients with the disease, initiated on either adalimumab (Humira) or etanercept (Enbrel) showed those with a higher body fat content at baseline were less likely to have responded to treatment at a mean follow-up of 14 months.

A lower chance of improvement on the Ankylosing Spondylitis Disease Activity Score containing CRP (ASDAS-CRP) was seen across a range of measures related to body fat including BMI, body fat percentage, fat mass, fat